肿瘤细胞治疗研究
英文原题：Safety and efficacy of DLL3 CAR-T cells armored with dnTGFBR2 in a subject with recurrent small-cell lung cancer: case report.
靶向 delta 样配体 3（DLL-3）的新型 CAR-T 疗法是广泛期 SCLC（ES-SCLC）患者有前景的治疗策略。
靶向delta样配体3（DLL-3）的新型CAR-T疗法是广泛期SCLC（ES-SCLC）患者有前景的治疗策略。我们报告了一例ES-SCLC患者，在不符合临床试验资格后，超说明书接受了研究性疗法LB2102。我们描述了她对治疗的阳性、长期反应。本案例凸显了在1期试验NCT05680922最终报告数据发布之前，该研究性药物在真实世界环境中的有效使用。
Novel CAR-T therapies targeting delta-like ligand 3 (DLL-3) are promising treatment strategies for individuals with extensive-stage SCLC (ES-SCLC). We report a case of a patient with ES-SCLC who received investigational therapy LB2102 off-label after becoming ineligible for a clinical trial. We described her positive, long-term response to treatment. This case highlights efficacious use of this investigational drug in a real-world setting prior to release of final reported data from phase 1 trial NCT05680922.
MEMBER ACCOUNT
登录成功会直接打开下一页。
